The pharmaceuticals company Glenmark Pharma Ltd introduce medicine for the time with the combination of  Teneligliptin (20mg) and Dapagliflozin (5mg/10mg) for the treatment of adult patients with type two diabetes, especially the ones with comorbidities.

• Ashoka Buildcon Shares Slump 3% Despite Securing Rs 410 Crore Project 
• Zydus Lifesciences Gets USFDA Nod; Stock Trades Flat
• Religare Enterprises Shares Slumped 6% on Demerger Plan 
• Natco Pharma Gets CDSCO Nod; Shares Rally 12.5%
• Lodha Developers Buys Solidrise for Rs 300 Cr; Shares Jump 1.5%

‘Zita D’ which contains Teneligliptin (20mg) andDapagliflozin (5 mg/10 mg). This medicine can be consumed by the patient once a day daily as per prescription, which helps to improve glycemic control and prevent complications in adult patients with type two diabetes, especially the ones with comorbidities, as per the statement said.